Get Free Quote

Delusional Disorder

Delusional disorder is a psychiatric condition characterized by one or more firmly held false beliefs. Protheragen is committed to providing cutting-edge diagnostic and therapeutic development solutions to address the challenges of delusional disorder management. As your reliable partner in delusional disorder therapeutic research, we provide comprehensive and high-quality services to meet all your scientific research needs.

Overview of Delusional Disorder

Delusional disorder is a psychotic disorder characterized by the presence of one or more non-bizarre delusions that persist for at least one month. Unlike schizophrenia, it does not typically involve prominent hallucinations, disorganized speech, or negative symptoms, and functioning remains relatively intact outside the domain of the delusion. Common subtypes include persecutory, jealous, somatic (e.g., delusional parasitosis), and erotomanic themes. The disorder often follows a chronic course, exhibits significant resistance to contradictory evidence, and poses considerable treatment challenges due to profound lack of insight.

Fig.1 Insights into the medical evaluation of delusional parasitosis (DP). (Mindru F M, et al., 2024)

Pathogenesis of Delusional Disorder

The pathogenesis of delusional disorder is multifactorial, involving a complex interplay of genetic, neurobiological, and environmental factors. Genetic predispositions link it to a broader psychosis spectrum, often implicating dysregulation in dopaminergic and serotonergic pathways, which alters salience attribution and reinforces false beliefs. Structural and functional abnormalities in prefrontal-limbic circuits impair reality testing and promote delusional consolidation. Environmental triggers, such as social isolation, sensory deficits, or chronic stress, frequently act as precipitating factors in genetically vulnerable individuals.

Pathophysiology of delusions and delirium in neurodegenerative diseases. Fig.2 Pathophysiological hypothesis about the etiology of delusions and delirium in neurodegenerative disorders. (Urso D, et al., 2022)

Therapeutic Development for Delusional Disorder

Drug Names	Mechanism of Action	Targets	Research Phase
Risperidone	Atypical antipsychotic; potent antagonist of dopamine and serotonin receptors.	Dopamine D2 receptors, Serotonin 5-HT2A receptors	Approved
Clozapine	Atypical antipsychotic; broad antagonist with high affinity for multiple serotonin, dopamine, adrenergic, and histamine receptors.	Dopamine D4 receptors, Serotonin 5-HT2A/2C/7 receptors, Adrenergic α1/2 receptors, Muscarinic M1 receptors, Histamine H1 receptors	Approved
Quetiapine	Atypical antipsychotic; antagonist with higher affinity for serotonin receptors than dopamine receptors.	Serotonin 5-HT2A receptors, Dopamine D2 receptors, Adrenergic α1/2 receptors, Histamine H1 receptors	Approved
Ziprasidone	Atypical antipsychotic; potent antagonist of dopamine and serotonin receptors; also inhibits serotonin and norepinephrine reuptake.	Dopamine D2 receptors, Serotonin 5-HT2A/1D/1B receptors, Serotonin and Norepinephrine Transporters (SERT/NET)	Approved

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

At Protheragen, we focus on preclinical research in delusional disorder, providing comprehensive solutions from biomarker identification to development of CNS targeted therapeutics. Our expertise covers disease modeling, including patient-derived iPSCs, genetically engineered models, and advanced blood-brain barrier (BBB) models for evaluating drug penetration and neuroprotective efficacy. We provide partners with target validation, lead compound optimization, and comprehensive preclinical research services.

Therapeutic Development Services

By Molecule Types

By Mechanism of Action

Disease Model Development Services

In Vitro Model Development
Patient-Derived Cell Model Development Neuronal Cell Model Development Glial Cell Model Development	Co-Culture Model Development Brain Organoid Development Spinal Cord Organoid Development
Microfluidic Model Development
Neurovascular Unit (NVU) Model Development Axon Degeneration Model Development Neuromuscular Junction (NMJ) Model Development	Neuroinflammation Model Development Synaptic Plasticity Model Development Organoid-on-a-Chip Model Development
Animal Model Development
GLDC Overexpression Model: This model involves increasing the copy number or expression of the glycine decarboxylase (GLDC) gene, which leads to reduced glycine availability and impaired NMDA receptor function, potentially contributing to psychotic-like behaviors. NPAS1/NPAS3 Knockout Model: This model utilizes genetic deletion of NPAS1 and NPAS3 genes, which are important for brain development and function, resulting in social deficits and altered behaviors such as erratic running and reduced social interaction.

At Protheragen, we are committed to validating and optimizing therapies for delusional disorder through comprehensive pharmacodynamics (PD), pharmacokinetics (PK) and toxicology research services to ensure their successful regulatory approval. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.

References

Mindru F M, Radu A F, Bumbu A G, et al. Insights into the medical evaluation of Ekbom syndrome: an overview[J]. International Journal of Molecular Sciences, 2024, 25(4): 2151.
Urso D, Gnoni V, Filardi M, et al. Delusion and delirium in neurodegenerative disorders: an overlooked relationship?[J]. Frontiers in psychiatry, 2022, 12: 808724.

For research use only. Not intended for any clinical use.